Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
A6NIE9
UPID:
PRS29_HUMAN
Alternative names:
Implantation serine proteinase 2-like protein
Alternative UPACC:
A6NIE9
Background:
Putative serine protease 29, also known as Implantation serine proteinase 2-like protein, represents a unique class of serine proteases. Despite limited information on its specific biological functions, its classification suggests a role in proteolytic processes, which are crucial in various physiological pathways including digestion, immune response, and blood coagulation.
Therapeutic significance:
Understanding the role of Putative serine protease 29 could open doors to potential therapeutic strategies. Its involvement in key biological processes hints at its potential as a target for drug discovery, aiming to modulate protease activity for therapeutic benefits.